Lv3
398 积分 2021-01-23 加入
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial
1个月前
已完结
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Eleven clinical trials that will shape medicine in 2026
1个月前
已完结
Notable advances 2025
1个月前
已完结
Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial
1个月前
已完结
Adjuvant treatment for melanoma
1个月前
已完结
Cutaneous Melanoma A Review
1个月前
已关闭
Two Cases of BRAF V600K Melanoma With Recurrence During Adjuvant Dabrafenib Plus Trametinib Therapy
1个月前
已完结
Redefining gastroesophageal junction cancer care with perioperative immunotherapy, minimal residual disease monitoring and new targets
1个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
